에서 실시간으로 운영 중이에요! 자세히 알아보기

Xtant Medical Holdings

XTNT

시가총액 US$4022만

0.2867 USD

-0.0161

5.32%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

0.2813

-0.0054

1.88%

1일

-5.32%

5일

-10.41%

1개월

-10.41%

3개월

-35.28%

6개월

-40.89%

연초 이후

-61.62%

1년

-59.51%

5년

-74.4%

10년

-97.61%

소개: Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

직원 수: 151

건강관리 제약 - 종합

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 100%

부정적 0%

Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

Partnership leverages BioHorizons' commercial network to broaden availability of Xtant's allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™ BELGRADE, Mont., Aug. 27, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced an exclusive partnership with BioHorizons (a Henry Schein, Inc. company), whereby BioHorizons will distribute Xtant's allogeneic growth factor technology under the private brand Prolifica™ through its commercial network.

Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Xtant Medical Reports Second Quarter 2026 Financial Results

Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast today, August 11 th, at 8:30am ET BELGRADE, Mont., Aug. 11, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the second quarter ended June 30, 2026.

Xtant Medical Reports Second Quarter 2026 Financial Results

Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the second quarter ended June 30, 2026, before the start of trading on Tuesday, August 11, 2026.

Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

BELGRADE, Mont., Aug. 4, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 46th Annual Growth Conference, which is being held August 11-13, 2026, in Boston.

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

Xtant Medical Q1 Earnings Call Highlights

Xtant Medical NYSEAMERICAN: XTNT raised its full-year 2026 revenue guidance after announcing a distribution agreement that moves the company into the hemostatic agent market, while first-quarter revenue declined from the prior-year period following divestitures and the loss of certain license revenue.

Xtant Medical Q1 Earnings Call Highlights

Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript

Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript

Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript

Xtant Medical Reports First Quarter 2026 Financial Results

Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon's U.S. sales team BELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026.

Xtant Medical Reports First Quarter 2026 Financial Results

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31, 2026, before the start of trading on Wednesday, May 13, 2026.

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium™ bone graft portfolio that is now available in pre‑shaped configurations designed to support handling, preparation, and placement across a range of surgical applications.

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.